Lithium
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Lithium
- Molecular weight
- 6.94
- Structure (SMILES)
These details could not be displayed.
- Belatacept Less Intensive (LI)
- belatacept less intensive li
- bi 201335 na 120mg qd li
- bi 201335 na 240 mg qd li
- lectro max powder 150
- LECTRO MAX POWDER 150
- li
- LI
- lithium
- Lithium
- LITHIUM [MI]
- LITHIUM [VANDF]
- Lithium [WHO-DD]
- lithium element
- LITHIUM ELEMENT
- lithium elemental
- lithium elemental hsdb
- lithium metallicum
- LITHIUM METALLICUM
- lithium mi
- lithium vandf
- lithium who dd
- LITHIUM, ELEMENTAL
- LITHIUM, ELEMENTAL [HSDB]
- ATC classification codes
- N05AN01
Sources for recorded values
- CAS registry numbers
- 7439-93-2
- ChEMBL ID
- CHEMBL1201333
- InChIKey
- WHXSMMKQMYFTQS-UHFFFAOYSA-N
- PubChem compound IDs
- 3028194
- RxNorm IDs (RxCUI)
- 6448
- FDA ingredient codes (UNII)
- 9FN79X2M3F
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- Li<sup>+</sup>
- Type
- Inorganic
Mechanisms of action
- Action type
- Inhibitor
- Target
- glycogen synthase kinase 3 beta
- Gene symbol
- glycogen synthase kinase 3 beta
- Condition
- Psychotic Disorders
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005407
- Subject identifier
- D011618
- Condition
- Bipolar Disorder
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0004985
- Subject identifier
- D001714
- Condition identifier
- EFO_0000702
- Condition identifier
- EFO_0004247
- Condition identifier
- EFO_0005407
- Condition identifier
- EFO_0007634
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009963
- Condition identifier
- EFO_0009963
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001904
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002050
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004985
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005485
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008119
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0010383
- Highest recorded phase
- 2
- Condition identifier
- Orphanet_2788
- Event
- action tremor
- Reports
- 22
- Reporting signal score
- 94.9613
- Event
- acute kidney injury
- Reports
- 270
- Reporting signal score
- 165.294
- Event
- aggression
- Reports
- 129
- Reporting signal score
- 127.685
- Event
- agitation
- Reports
- 230
- Reporting signal score
- 244.12
- Event
- akathisia
- Reports
- 145
- Reporting signal score
- 321.597
- Event
- ataxia
- Reports
- 198
- Reporting signal score
- 436.807
- Event
- bipolar disorder
- Reports
- 59
- Reporting signal score
- 110.639
- Event
- blood creatinine increased
- Reports
- 168
- Reporting signal score
- 138.3
- Event
- catatonia
- Reports
- 88
- Reporting signal score
- 207.315
- Event
- cerebellar syndrome
- Reports
- 41
- Reporting signal score
- 88.404
- Event
- chronic kidney disease
- Reports
- 105
- Reporting signal score
- 148.013
- Event
- cognitive disorder
- Reports
- 124
- Reporting signal score
- 135.558
- Event
- cogwheel rigidity
- Reports
- 34
- Reporting signal score
- 98.2283
- Event
- confusional state
- Reports
- 403
- Reporting signal score
- 406.956
- Event
- coordination abnormal
- Reports
- 71
- Reporting signal score
- 118.495
- Event
- decreased eye contact
- Reports
- 24
- Reporting signal score
- 98.0738
- Event
- dehydration
- Reports
- 190
- Reporting signal score
- 95.0443
- Event
- delirium
- Reports
- 172
- Reporting signal score
- 226.693
- Event
- delusion
- Reports
- 71
- Reporting signal score
- 102.024
- Event
- diabetes insipidus
- Reports
- 88
- Reporting signal score
- 281.168
- Event
- disinhibition
- Reports
- 76
- Reporting signal score
- 247.245
- Event
- disorientation
- Reports
- 158
- Reporting signal score
- 203.114
- Event
- disturbance in attention
- Reports
- 93
- Reporting signal score
- 83.6867
- Event
- drug interaction
- Reports
- 510
- Reporting signal score
- 464.445
- Event
- dysarthria
- Reports
- 216
- Reporting signal score
- 326.147
And 53 more, listed on the interactive page.
- NCT00081380
- NCT00226135
- NCT00868452
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- Yes
- Heavy atoms
- 1
- Molecular formula
- Li
- Monoisotopic mass
- 7.01600343
- Natural product
- Yes
Related records
Trials (103)
- A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,Study
- A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer
- A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects
- A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration
- A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
- A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants
- Acute Treatment of Bipolar II Depression
- Adult Bipolar Mania
- Algorithm Guided Treatment Strategies for Bipolar Depression
- Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode
- Bioequivalency Study of 300 mg Lithium Carbonate Under Fasting Conditions
- Bioequivalency Study of 300 mg Lithium Carbonate Under Fed Conditions
- Bioequivalency Study of 450 mg Lithium Carbonate Under Fasting Conditions
- Bioequivalency Study of 450 mg Lithium Carbonate Under Fed Conditions
- Combination Therapy for the Treatment of Bipolar Disorders
- Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling
- Comparative Effectiveness Study for Bipolar Disorder
- Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania
- Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
- Continuation Ketamine in Major Depression
In development for (7)
- Bipolar disorder Phase 3
- Colorectal cancer Phase 1
- Depressive disorder Phase 3
- Fragile X syndrome Phase 2
- Major depressive disorder Phase 3
- Psychotic disorder Phase 3
- Spinocerebellar ataxia type 1 Phase 1
Other linked conditions (3)
- Mood disorder
- Osteoporosis-pseudoglioma syndrome
- Small cell lung carcinoma